Clinical Trials
169 trialsTrametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Natural History Study of Patients With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
INSPIRE-NF1
Healx Limited
Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
National Institutes of Health Clinical Center (CC)
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Gait in Young Children With NF1
NYU Langone Health
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
Cedars-Sinai Medical Center
ReNeu
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
National Institutes of Health Clinical Center (CC)
Real-World Treatment Study of Koselugo (Selumetinib)
AstraZeneca
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
National Institutes of Health Clinical Center (CC)
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
National Institutes of Health Clinical Center (CC)
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
National Institutes of Health Clinical Center (CC)
SJFAMILY
St. Jude Children's Research Hospital
Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)
Massachusetts General Hospital
NF1NAC
Children's Hospital Medical Center, Cincinnati
PRECIOUS Egypt
AstraZeneca
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
National Cancer Institute (NCI)
NF118
University of Alabama at Birmingham
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
KOMET
AstraZeneca
PASS of Paediatric Patients Initiating Selumetinib
AstraZeneca
NF114
University of Alabama at Birmingham
NF113
University of Alabama at Birmingham
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)
Massachusetts General Hospital
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
Massachusetts General Hospital
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
National Institutes of Health Clinical Center (CC)
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NFlection Therapeutics, Inc.
FARD
Institut National de la Santé Et de la Recherche Médicale, France
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
University of Alabama at Birmingham
NF-1, Nutraceutical Intervention
Masonic Cancer Center, University of Minnesota
Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
Johns Hopkins University
NF1-TED
Boston Children's Hospital
Precision Medicine for Neurocutaneous Syndromes in Western China
West China Hospital
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Massachusetts General Hospital
RASopathy Biorepository
Children's Hospital Medical Center, Cincinnati
SPRINKLE
AstraZeneca
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
Stanford University
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital